DNAY News and Press, Codex DNA Inc.

Telesis Bio press release ( NASDAQ: DNAY ): Q3 GAAP EPS of -$0.42 beats by $0.05 . Revenue of $6.68M (+138.6% Y/Y) beats by $1.38M . 2022 Financial Guidance Revenue is now expected to be between $23 million and $25 million, an increase from previous guidanc...

-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE N...

SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction ...

SAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, and Cellibre, a leading manufacturing technology company, today announced initiation of work under a collaboration to optimize the development and valid...

SAN DIEGO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced a plan to change its Company name to Telesis Bio. “Our innovative and pioneering spirit, and the versatility and power ...

SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced commercial release of BioXp ® Error-corrected Libraries kits that enable researchers to automate synthesis of DNA variant librarie...

SAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, will showcase its recently released BioXp™ 9600 system at the World of Technology & Science conference which begins tomorrow in Utrecht, N...

SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced commercial release and first shipment of the BioXp™ 9600 system, a next-generation high throughput platform designed to revolu...

Codex DNA, Inc. (DNAY) Q2 2022 Earnings Conference Call August 09, 2022 04:30 PM ET Company Participants Todd Nelson - Chief Executive Officer Brent Hunter - VP of Finance Conference Call Participants Brandon Couillard - Jefferies Presentation ...

Image source: The Motley Fool. Codex DNA, Inc. (NASDAQ: DNAY) Q2 2022 Earnings Call Aug 09, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Codex DNA, Inc. (DNAY) Q2 2022 Earnings Call Transcript